參考文獻(xiàn)/References:
[1] Colombo N,Peiretti M,Garbi A,et al.ESMO guidelines working group.non epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow up [J].Ann Oncol,2012,23(Suppl 7):20-26.
[2] 程峰,朱筧青.卵巢癌減瘤術(shù)結(jié)局及病理分期與術(shù)前血細(xì)胞計(jì)數(shù)的關(guān)系[J].中國(guó)醫(yī)師雜志,2017,19(1): 83-85.
[3] 趙誼寧,陶陶,張力杰,等.雌激素受體ERα及ERβ與腫瘤關(guān)系的研究進(jìn)展[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2016,35(3):418-422.
[4] 黃海偉,謝虹,馬新,等.miR-26b在卵巢癌組織中的表達(dá)水平及其與預(yù)后的關(guān)系[J].中國(guó)婦幼保健,2018,33(19):4507-4509.
[5] 陳誠(chéng),游雪云,付子毅.miR-26b在卵巢癌組織中的表達(dá)與功能[J].中國(guó)老年學(xué)雜志, 2017,37(1):15-17.
[6] 葉旭,李力.miRNA在卵巢癌早期診斷和預(yù)后中作用的研究進(jìn)展[J].中國(guó)腫瘤生物治療雜志,2019,26(6):715-719.
[7] 高瑤,鄒霞,高軍.miRNA在卵巢癌診治及預(yù)后預(yù)測(cè)中作用的研究進(jìn)展[J].山東醫(yī)藥,2019,59(3):87-90.
[8] Casimiro M C,Velasco-Velázquez M,Aguirre-Alvarado C,et al.Overview of cyclins D1 function in cancer and the CDK inhibitor landscape:past and present [J].Expert Opin Investig Drugs,2014,23(3):295-304.
[9] Kanter M,Turan G,Usta C,et al.Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms [J].J Mol Histol,2016,47(2):145-152.
[10] 胡觀麗,張晶波,董潔,等.雌激素受體α、β及細(xì)胞周期蛋白D1、癌基因蛋白質(zhì)P21在子宮內(nèi)膜癌組織中的表達(dá)及臨床意義[J].安徽醫(yī)藥,2019,23(9):1769-1773.
[11] Iwona K A,lina R,Anna F,et al.PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients [J].Cancer Biology&Therapy,2009,8(1):1-6.
[12] Chan K K,Leung T H,Chan D W,et al.Targeting estrogen receptor subtypes(ERα and ERβ)with selective ER modulators in ovarian cancer [J].J Endocrinol,2014,221(2):325-336.